Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 418
- 试验地点
- 112
- 主要终点
- Incidence of adverse events (AEs)
研究概览
简要总结
This is an open-label, single-arm, multicenter, Phase IIIb study to evaluate the safety and tolerability of Herceptin SC in combination with Perjeta IV plus docetaxel in female patients with HER2-positive metastatic or locally recurrent breast cancer. Enrolled patients are to receive study medication until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end, whichever occurs first. The anticipated time on study treatment is approximately 24 months. The target sample size is 400.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed and documented adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection. Patients with measurable and/or non-measurable disease evaluable according to Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 are eligible.
- •HER2-positive disease (defined as either immunohistochemistry [IHC] 3 + or in situ hybridization [ISH] positive) as assessed by local laboratory on primary tumor or metastatic site if primary tumor not available
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- •Left ventricular ejection fraction (LVEF) of at least 50%
- •Negative serum pregnancy test result at baseline and use of effective contraception as defined by the protocol
排除标准
- •Previous systemic non-hormonal anti-cancer therapy for the metastatic or locally recurrent disease. Note: Prior to study entry, up to two lines of hormonal therapy for metastatic or locally recurrent disease are permitted, one of which may be in combination with everolimus.
- •Disease-free interval of less than 6 months from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence of breast cancer
- •Previous approved or investigative anti-HER2 agents as neoadjuvant or adjuvant therapy for any breast cancer treatment, except Herceptin
- •History of persistent Grade 2 or higher hematological toxicity resulting from previous adjuvant or neoadjuvant therapy
- •Radiographic evidence of central nervous system (CNS) metastases as assessed by computed tomography (CT) or magnetic resonance imaging (MRI), unless they have been treated and have been stable for at least 3 months and do not require ongoing corticosteroid treatment
- •Current peripheral neuropathy of Grade 3 or greater
- •History of other malignancy within the last 5 years prior to first dose of study drug administration, except for carcinoma in situ of the cervix or basal cell carcinoma
- •Inadequate organ function
- •Uncontrolled hypertension with or without medication
- •Clinically significant cardiovascular disease
- •History of LVEF decline to below 50% during or after prior Herceptin neo-adjuvant or adjuvant therapy
- •Current known infection with HIV, hepatitis B virus, or hepatitis C virus
- •Severe uncontrolled concomitant disease that would contraindicate the use of any of the investigational drugs used in this study or that would put the patient at high risk for treatment-related complications, including severe pulmonary conditions/illness
- •Pregnant or lactating women
- •Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy
- •History of receiving any investigational treatment within 28 days prior to first dose of study drug administration (dosing) or concurrent participation in any interventional clinical trial
研究组 & 干预措施
Herceptin SC + Perjeta IV + docetaxel IV
Single arm
干预措施: Docetaxel (Drug)
Herceptin SC + Perjeta IV + docetaxel IV
Single arm
干预措施: pertuzumab [Perjeta] (Drug)
Herceptin SC + Perjeta IV + docetaxel IV
Single arm
干预措施: trastuzumab [Herceptin] (Drug)
结局指标
主要结局
Incidence of adverse events (AEs)
时间窗: Up to 24 months after the last patient has been enrolled, approximately 3.5 years
Incidence and severity of adverse events Grade >/= 3, according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0
时间窗: Up to 24 months after the last patient has been enrolled, approximately 3.5 years
Incidence of cardiac events (composite outcome measure): congestive heart failure (CHF) and cardiac death
时间窗: Up to 24 months after the last patient has been enrolled, approximately 3.5 years
次要结局
- Progression-free survival, tumor assessments according to RECIST v1.1(Up to 3.5 years)
- Incidence of anti-Herceptin, anti-rHuPH20 antibodies(Up to 3.5 years)
- Overall survival(Up to 3.5 years)
- Objective response rate, defined as a complete response (CR) or a partial response (PR)(Up to 3.5 years)